Nexalin Technology, Inc. (NASDAQ:NXL) announced a peer-reviewed study published in BMC Psychiatry showcasing the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology. The study focused on six female adolescents with non-suicidal self-injury (NSSI), revealing that the 77.5 Hz high-gamma stimulation led to significant reductions in self-injury behaviors and depressive symptoms. Additionally, measurable changes in brain-network activity were noted, particularly in emotional-control networks such as the Default, Limbic, and Salience/Ventral Attention networks. Improvements in anxiety and sleep quality were also reported, with only one mild headache as an adverse effect. Nexalin executives emphasized the importance of these findings in addressing treatment-resistant mental health issues and the growing demand for drug-free alternatives. The company recently launched its AI-designed virtual clinic platform, NeuroCare, in collaboration with the University of California, San Diego, aiming to enhance patient access and long-term care in brain health. As of the last trading session, Nexalin shares closed at $0.35.